HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Califf's Priorities Feature Short- And Long-Term Goals Despite Potentially Brief Tenure

This article was originally published in The Rose Sheet

Executive Summary

Newly confirmed FDA Commissioner Robert Califf should not assume he will be leaving once a new president arrives, a Republican-appointed predecessor says.

You may also be interested in...



Califf Returns To US FDA Helm As Familiar Consumer Health Regulation Problems Continue

Announcement of Senate confirmation of Robert Califf as commissioner came shortly after FDA announced recalls of products labeled as supplements but spiked with ED drugs. Like those and others recently identified as adulterated, supplements with undisclosed drugs were being found during Califf’s first stint in 2016 and 2017.

EWG To FDA Commish: Sunscreen SPFs Require ‘Urgent’ Investigation

The Environmental Working Group renews its call for a cap on SPF values at 50+, asking FDA to investigate whether anti-inflammatory ingredients added to sunscreen formulations are boosting SPFs without providing meaningful protection against UV damage. The NGO also recommends changes to the agency’s SPF testing requirements to improve the accuracy of labeled SPF claims.

EWG Lobbyists Keep Eye On Prize: The Personal Care Products Safety Act

The Environmental Working Group is working with industry leaders to urge the Senate HELP Committee to take up the PCPSA "as soon as possible," the NGO says. EWG's Scott Faber noted in an interview that "there are very few issues pending before the Senate that are bipartisan and that have the support of both industry and public health organizations," which could work in the bill's favor in a challenging Congress.

Related Content

Topics

Latest News
UsernamePublicRestriction

Register

RS019821

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel